OpGen Inc (OPGN) Rating Lowered to Hold at Zacks Investment Research
OpGen Inc (NASDAQ:OPGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
Several other brokerages have also recently commented on OPGN. HC Wainwright set a $1.00 target price on OpGen and gave the stock a “buy” rating in a report on Tuesday, July 18th. Dawson James reissued a “buy” rating on shares of OpGen in a report on Monday, June 19th.
Shares of OpGen (OPGN) opened at 0.2822 on Wednesday. OpGen has a 12-month low of $0.27 and a 12-month high of $3.10. The company has a 50 day moving average price of $0.31 and a 200-day moving average price of $0.71. The firm’s market cap is $14.55 million.
TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/09/15/opgen-inc-opgn-rating-lowered-to-hold-at-zacks-investment-research.html.
In other news, Chairman Jven Capital, Llc bought 1,875,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 18th. The shares were purchased at an average price of $0.40 per share, with a total value of $750,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Timothy C. Dec bought 65,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 18th. The shares were purchased at an average cost of $0.40 per share, for a total transaction of $26,000.00. Following the acquisition, the chief financial officer now owns 118,966 shares of the company’s stock, valued at $47,586.40. The disclosure for this purchase can be found here. 53.27% of the stock is owned by insiders.
An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. increased its position in shares of OpGen Inc (NASDAQ:OPGN) by 1.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned 1.25% of OpGen worth $219,000 at the end of the most recent quarter. 8.13% of the stock is currently owned by institutional investors.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.